Evidence map›Paper›PMID 28029757›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2017

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.

Peter A Merkel, Gang Xie, Paul A Monach, Xuemei Ji, Dominic J Ciavatta, Jinyoung Byun, Benjamin D Pinder, Ai Zhao, Jinyi Zhang, Yohannes Tadesse and 35 more

Open access · hybridAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 178 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Potential impact of two functional variants in theCaspian journal of internal medicine · 2026
    Article
  9. Article
  10. PeerJ · 2026
    Article
  11. Article
  12. Review
  13. Can we cure vasculitis?Current opinion in immunology · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 4 countries.

Peter A MerkelUniversity of Pennsylvania, Philadelphia.
Gang XieMount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute and Toronto General Research Institute, Toronto, Ontario, Canada.
Paul A MonachBoston University and VA Boston Healthcare System, Boston, Massachusetts.
Xuemei JiDartmouth College, Lebanon, New Hampshire.
Dominic J CiavattaUniversity of North Carolina, Chapel Hill.
Jinyoung ByunDartmouth College, Lebanon, New Hampshire.
Benjamin D PinderMount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute and Toronto General Research Institute, Toronto, Ontario, Canada.
Ai ZhaoMount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute and Toronto General Research Institute, Toronto, Ontario, Canada.
Jinyi ZhangMount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto General Research Institute and University of Toronto, Toronto, Ontario, Canada.
Yohannes TadesseMount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute and Toronto General Research Institute, Toronto, Ontario, Canada.
David QianDartmouth College, Lebanon, New Hampshire.
Matthew WeirauchCincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Rajan NairUniversity of Michigan, Ann Arbor.
Alex TsoiUniversity of Michigan, Ann Arbor.
Christian PagnouxMount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.
Simon CaretteMount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.
Sharon ChungUniversity of California, San Francisco.
David CuthbertsonUniversity of South Florida, Tampa.
John C DavisUniversity of California, San Francisco.
Paul F DellaripaBrigham and Women's Hospital, Boston, Massachusetts.
Lindsy ForbessCedars-Sinai Medical Center, West Hollywood, California.
Ora Gewurz-SingerUniversity of Michigan, Ann Arbor.
Gary S HoffmanCleveland Clinic, Cleveland, Ohio.
Nader KhalidiMcMaster University, Hamilton, Ontario, Canada.
Curry KoeningUniversity of Utah, Salt Lake City.
Carol A LangfordCleveland Clinic, Cleveland, Ohio.
Alfred D MahrHôpital Saint-Louis, Paris, France.
Carol McAlearUniversity of Pennsylvania, Philadelphia.
Larry MorelandUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
E Philip SeoJohns Hopkins University, Baltimore, Maryland.
Ulrich SpecksMayo Clinic, Rochester, Minnesota.
Robert F SpieraHospital for Special Surgery, New York, New York.
Antoine SreihUniversity of Pennsylvania, Philadelphia.
E William St ClairDuke University Medical Center, Durham, North Carolina.
John H StoneMassachusetts General Hospital, Boston.
Steven R YtterbergMayo Clinic, Rochester, Minnesota.
James T ElderUniversity of Michigan and Ann Arbor VA Hospital, Ann Arbor, Michigan.
Jia QuWenzhou Medical University, Wenzhou, China.
Toshiki OchiUniversity of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Naoto HiranoUniversity of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Jeffrey C EdbergUniversity of Alabama at Birmingham.
Ronald J FalkUniversity of North Carolina, Chapel Hill.
Christopher I AmosDartmouth College, Lebanon, New Hampshire.
Katherine A SiminovitchMount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto General Research Institute and University of Toronto, Toronto, Ontario, Canada.
Vasculitis Clinical Research Consortium
Dartmouth College · USLunenfeld-Tanenbaum Research Institute · CAMount Sinai Hospital · CAPhiladelphia University · USUniversity of Michigan–Ann Arbor · USCleveland Clinic · USMayo Clinic · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CAAnn Arbor VA Medical Center · USBrigham and Women's Hospital · USCedars-Sinai Medical Center · USCincinnati Children's Hospital Medical Center · USDuke Medical Center · USHôpital Saint-Louis · FRHospital for Special Surgery · USJohns Hopkins University · USMassachusetts General Hospital · USMcMaster University · CA

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
ZINC GLUCONATE GLYCINE LOZENGES &VITAMIN C EFFECTS ON COMMON COLDM01RR000042 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RUBENFIRE, MELVYN · 1985 to 2007
$40.8M
Rare Diseases Data Management and Coordinating CenterU01TR001263 · NCATS · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2014 to 2018
$28.1M
Translation of Knowledge on the Pathogenesis of ANCA Disease into NovelP01DK058335 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JENNETTE, CHARLES · 2000 to 2019
$25.9M
VCRC-VF FellowshipU54AR057319 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI MERKEL, PETER A · 2009 to 2020
$12.5M
Linkage analysis of familial psoriasis(Supplement)R01AR042742 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELDER, JAMES TILFORD · 1994 to 2021
$10.1M
Genetic and Genomic Dissection of Psoriatic ArthritisR01AR063611 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELDER, JAMES TILFORD, GLADMAN, DAFNA D · 2012 to 2023
$6.2M
VASCULITIS CLINICAL RESEARCH NETWORK (VCRN): RARE DISEASEU54RR019497 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A · 2003 to 2008
$6.1M
Training Program for Quantitative Population Sciences in CancerR25CA134286 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA, TOSTESON, TOR D · 2009 to 2018
$3.0M
Functional Genomics of PsoriasisR01AR065183 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELDER, JAMES TILFORD · 2013 to 2016
$1.7M
Genetic Polymorphisms in Wegener's GranulomatosisR01AR047799 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI EDBERG, JEFFREY C. · 2000 to 2003
$1.2M
NCATS NIH HHS U01 TR001263NCATS NIH HHS UL1 TR000439NCI NIH HHS P30 CA023108NCI NIH HHS R25 CA134286NCRR NIH HHS M01 RR000042NCRR NIH HHS U54 RR019497NIAMS NIH HHS K23 AR063126NIAMS NIH HHS R01 AR042742NIAMS NIH HHS R01 AR047799NIAMS NIH HHS R01 AR063611NIAMS NIH HHS R01 AR065183NIAMS NIH HHS U54 AR057319NIDDK NIH HHS P01 DK058335
6 · The paper itself

Abstract

objectiveTo identify risk alleles relevant to the causal and biologic mechanisms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

methodsA genome-wide association study and subsequent replication study were conducted in a total cohort of 1,986 cases of AAV (patients with granulomatosis with polyangiitis [Wegener's] [GPA] or microscopic polyangiitis [MPA]) and 4,723 healthy controls. Meta-analysis of these data sets and functional annotation of identified risk loci were performed, and candidate disease variants with unknown functional effects were investigated for their impact on gene expression and/or protein function.

resultsAmong the genome-wide significant associations identified, the largest effect on risk of AAV came from the single-nucleotide polymorphism variants rs141530233 and rs1042169 at the HLA-DPB1 locus (odds ratio [OR] 2.99 and OR 2.82, respectively) which, together with a third variant, rs386699872, constitute a triallelic risk haplotype associated with reduced expression of the HLA-DPB1 gene and HLA-DP protein in B cells and monocytes and with increased frequency of complementary proteinase 3 (PR3)-reactive T cells relative to that in carriers of the protective haplotype. Significant associations were also observed at the SERPINA1 and PTPN22 loci, the peak signals arising from functionally relevant missense variants, and at PRTN3, in which the top-scoring variant correlated with increased PRTN3 expression in neutrophils. Effects of individual loci on AAV risk differed between patients with GPA and those with MPA or between patients with PR3-ANCAs and those with myeloperoxidase-ANCAs, but the collective population attributable fraction for these variants was substantive, at 77%.

conclusionThis study reveals the association of susceptibility to GPA and MPA with functional gene variants that explain much of the genetic etiology of AAV, could influence and possibly be predictors of the clinical presentation, and appear to alter immune cell proteins and responses likely to be key factors in the pathogenesis of AAV.

Indexed as

Adultalpha 1-AntitrypsinAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAutoantigensB-LymphocytesCase-Control StudiesFemaleGene ExpressionGenetic Predisposition to DiseaseGenome-Wide Association StudyGranulomatosis with PolyangiitisHaplotypesHLA-DP AntigensHLA-DP beta-ChainsHumansMalealpha 1-AntitrypsinAutoantigensHLA-DP AntigensHLA-DPB1 antigenHLA-DP beta-ChainsMyeloblastinPeroxidaseProtein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, humanSERPINA1 protein, human

Identifiers

PMID28029757
PMCPMC5434905
OpenAlexW2567331551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.